Advertisement

Topics

Galt Company Profile

01:05 EDT 19th June 2018 | BioPortfolio

Every situation—whether you are responding to a regulatory requirement, addressing a competitor challenge, or augmenting your surveillance and signaling resources—calls for a distinct approach. Galt’s team of medical, scientific and technical experts will work with you to design an efficient solution that best meets your unique needs. Galt’s expertise covers the full benefit/risk spectrum, including:
Adverse event coding and electronic submission
Risk management and safety data analysis
Competitive intelligence, safety surveillance and monitoring
Pharmacoepidemiology and innovative communication solutions
At Galt, our solutions allow us to deliver results quickly, while our industry expertise ensures those results are useful

Location

46040 Center Oak Plaza, Suite 100
Sterling
Virginia
20166
United States of America

Contact

Phone: 703-421-6720
Fax: 703-421-6708
Email: info@drugsafety.com


News Articles [10 Associated News Articles listed on BioPortfolio]

Galectin Therapeutics (GALT) Presents At BIO CEO & Investor Conference - Slideshow

Galectin Therapeutics (GALT) Presents At 30th Annual ROTH Conference - Slideshow

Galectin Therapeutics (GALT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow

FOMX To Report Data In Q3, INNT Continues To Sizzle, All Eyes On GALT

The following are some of today's top gainers in the pharma/biotech sector.

GALT Vaults As NASH Research Sparks Interest, MDGL Abuzz, MACK Awaits Data

The following are some of today's top gainers in the pharma/biotech sector.

Sun Trolley Temporarily Suspends Galt Link

"Over the next eighteen months, the existing route as well as different route alignments and service schedules will be analyzed," said Robyn Chiarelli, Executive Read more...

Nestlé-Aktie: Doch keine Übernahme von Merck-Sparte!

Liebe Leser, bisher galt das Unternehmen Nestlé als einer der Kaufinteressenten für den rezeptfreien Medikamentenbereich von Merck. Nun scheint der Schweizer Industriekonzerns jedoch einen Rückzieh...

TENX Heartened After Meeting With FDA, RXII To Report Data In May, GALT On Watch

Tenax Therapeutics gained over 47% on Wednesday after it announced that it had a productive pre-Investigational New Drug (pre-IND) meeting with the FDA for a phase II study of Levosimendan in Pulmonar...

Drugs and Medications [0 Results]

None

PubMed Articles [7 Associated PubMed Articles listed on BioPortfolio]

Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71.

GALT is an important antigen of Actinobacillus pleuropneumoniae (APP), which was shown to provide partial protection against APP infection in a previous study in our lab. The main purpose of the prese...

Gut-associated Lymphoid Tissue (GALT) Carcinoma in Ulcerative Colitis.

In ulcerative colitis (UC), the majority of colorectal carcinomas (CRC) arise in the vast colorectal mucosal domain built with mucus-producing goblet cells and columnar cells. Conversely, CRC in UC ra...

Cell-free Fluorescent Intra-Golgi Retrograde Vesicle Trafficking Assay.

Intra-Golgi retrograde vesicle transport is used to traffic and sort resident Golgi enzymes to their appropriate cisternal locations. An assay was established to investigate the molecular details of v...

HIV replication is associated to inflammasomes activation, IL-1β, IL-18 and caspase-1 expression in GALT and peripheral blood.

Human immunodeficiency virus (HIV) promotes an inflammatory process, leading to the progressive loss of the functional capacity of the immune system. The HIV infection induces alterations in several t...

Methods for the Detection, Study, and Dynamic Profiling of O-GlcNAc Glycosylation.

The addition of O-linked β-N-acetylglucosamine (O-GlcNAc) to serine/threonine residues of proteins is a ubiquitous posttranslational modification found in all multicellular organisms. Like phosphoryl...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study

HIV-1 cannot be eradicated from infected individuals by current antiretroviral regimens. Cellular reservoirs and tissue sanctuary sites allow latent HIV-1 persistence and ongoing low-level...

The Lymphoid Tissue Pharmacology of Antiretroviral Drugs

Hypothesis: Antiretroviral drugs (ARVs) with enhanced LT penetration characteristics in vitro and in macaques will translate into an ARV regimen with increased LN and GALT concentrations ...

Predictors of Time to Viremia With an Analytic Treatment Interruption

This is a two-center study of 30 HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years. Participants will be asked to undergo LN and GALT biopsies...

HIV Persistence and Viral Reservoirs

Although highly active antiretroviral therapy (HAART) decreases HIV-associated mortality, it does not to completely restore health. Patients doing well on otherwise effective HAART remain...

Impact of Pre-ART Blood CD4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men

Although combined antiretroviral therapy (cART) has dramatically improved quality of life and lifespan of HIV infected individuals, it still fails to eliminate viral reservoirs. The Gut As...

Companies [6 Associated Companies listed on BioPortfolio]

Galt Associates, Inc

Every situation—whether you are responding to a regulatory requirement, addressing a competitor challenge, or augmenting your surveillance and signaling resources—calls for a distinct approach. Ga...

Galt

Every situation—whether you are responding to a regulatory requirement, addressing a competitor challenge, or augmenting your surveillance and signaling resources—calls for a distinct approach. Ga...

Galt Medical

Galt Medical (www.galtmedical.com), a wholly-owned subsidiary of Theragenics Corporation® (www.theragenics.com), manufactures and distributes vascular access products used in ...

Galectin Therapeutics Inc.

Galectin Therapeutics is focusing its galectin inhibitor development efforts in two key disease areas: fibrosis and cancer.

Galectin Therapeutics, Inc.

Galectin Therapeutics (OTC: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company’s unique understanding of ga...

More Information about "Galt" on BioPortfolio

We have published hundreds of Galt news stories on BioPortfolio along with dozens of Galt Clinical Trials and PubMed Articles about Galt for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Galt Companies in our database. You can also find out about relevant Galt Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record